Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

The EMA has approved Moleculin Biotech’s CTA for a Phase IIb/III trial of Annamycin plus cytarabine (Ara-C) for AML.

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...